TNT-i  (Synonyms: NPD3064)

TNT-i (NPD3064) is an inhibitor targeting M-Sec. TNT-i inhibits M-Sec-induced tunneling nanotube (TNT) formation reversibly. TNT-i reduces wild-type HIV-1 production in macrophages and M-Sec-expressing T cells. TNT-i shows low cytotoxic effects on macrophages and T cells. TNT-i can be used for the research of HIV-1 infection^[1].

TNT-i (10 μM; 24 h) potently and reversibly inhibits M-Sec-induced TNT formation in GFP-M-Sec-transfected HeLa cells^[1].
TNT-i (3-10 μM; 3 days) dose-dependently reduces TNT formation in wild-type HIV-1 JRFL-infected human monocyte-derived macrophages, with a 50% reduction observed after 3 days of incubation^[1].
TNT-i (3-10 μM; 3 days) reduces wild-type HIV-1 production by approximately 50% in human monocyte-derived macrophages, with no effect on Nef-deficient HIV-1 production or MDM cell survival^[1].
TNT-i (10 μM; 4 days) reduces wild-type HIV-1 production by approximately 50% in M-Sec-positive MT-2 T cells, with no effect on Nef-deficient HIV-1 production or MT-2 cell survival^[1].
TNT-i (10 μM; 24 h) does not inhibit Nef-mediated downregulation of cell-surface CD4 or MHC I in 293-CD4 cells, indicating it does not target Nef's core regulatory functions^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

381.31

C₁₈H₂₅BrN₂O₂

Solid

CC[C@]1(C2)C[N@@](C(C3=CC(Br)=CC=C3O)[N@@]2C4)C[C@]4(CC)C1O

Room temperature in continental US; may vary elsewhere.

• [1]. Hashimoto M, et al. Potential Role of the Formation of Tunneling Nanotubes in HIV-1 Spread in Macrophages. J Immunol. 2016;196(4):1832-1841.